What the tingling feels like, and what it’s called
Dysaesthesia is the medical term for an unusual or unpleasant skin sensation.
Wegovy’s UK product information records these sensations together as altered skin sensation.2
The terms it lists are dysaesthesia, paraesthesia (pins and needles), hyperaesthesia (heightened sensitivity), a burning sensation, allodynia (pain from something that shouldn’t hurt, such as clothing brushing the skin), and sensitive skin.2
Some people notice pins and needles or prickling, and others describe skin that feels mildly sunburnt or that stings when they touch it.
It’s most often noticed in the hands, fingers, and feet, though it can appear elsewhere, including across the back and torso. It tends to come and go rather than being there all the time.
Because the number of people affected rises with the dose, it’s more likely to appear after a dose increase.3
How common it is at each dose
Tingling was far less common at the 2.4 mg dose of Wegovy than at the newer 7.2 mg dose.
STEP UP, the phase 3b trial (a large human study) that compared the two doses in 1,407 adults living with obesity, reported these sensations in:1
- 22.9% of people on Wegovy 7.2 mg
- 6.0% of people on Wegovy 2.4 mg
- 0.5% of people on a placebo (1 participant out of 201)
That’s close to four times as many people on 7.2 mg as on 2.4 mg, which is why this side effect has become associated with the higher dose.
A second trial, STEP UP T2D, tested the same two doses in 512 adults living with obesity and type 2 diabetes and found a similar pattern of increasing tingling sensations at the higher dose, at 18.9% on 7.2 mg and 4.9% on 2.4 mg.4
| Group |
Reported altered skin sensations |
Trial |
| Wegovy 7.2 mg |
22.9% |
STEP UP |
| Wegovy 2.4 mg |
6.0% |
STEP UP |
| Placebo |
0.5% |
STEP UP |
| Wegovy 7.2 mg, with type 2 diabetes |
18.9% |
STEP UP T2D |
| Wegovy 2.4 mg, with type 2 diabetes |
4.9% |
STEP UP T2D |
| Placebo, with type 2 diabetes |
No new events reported |
STEP UP T2D |
Even at the higher dose, few people stopped because of it. Four people in the 7.2 mg group of around 1,000 stopped taking Wegovy permanently because of these sensations, and nobody in the 2.4 mg or placebo groups did.1
Most people who developed these sensations carried on with treatment, though 23% of them had their dose reduced.3
Why the Wegovy leaflet describes it as uncommon
Wegovy’s product information lists dysaesthesia as an uncommon side effect, a category meaning it affects between 0.1% and 1% of people.2
That frequency comes from the earlier trial programme, which tested doses up to 2.4 mg, so it describes the previously highest dose rather than the new highest dose of 7.2 mg.
The same document adds a footnote saying the frequency is higher at 7.2 mg, and quotes 21.6% for that dose against 0.3% on placebo.2
Is it a sign of nerve damage?
Tingling and numbness can also be signs of nerve damage, or peripheral neuropathy.
Dysaesthesia describes the abnormal sensation itself, while peripheral neuropathy is damage to the nerves, which usually causes loss of sensation, weakness, or difficulty with balance alongside the abnormal feelings.
Wegovy’s UK product information lists dysaesthesia as a side effect, and doesn’t list peripheral neuropathy.2
In STEP UP, most of these events were mild to moderate, and most people recovered while they stayed on Wegovy.1 The UK product information reports the same.2
Among people on 7.2 mg who developed them, 18% hadn’t recovered by the time the 72-week trial finished.3 Tell your prescriber if you experience tingling sensations that aren’t improving.
Tingling and numbness also have causes that have nothing to do with Wegovy, including low vitamin B12, a trapped nerve, and diabetes that hasn’t been diagnosed. So numbness that persists or worsens should be assessed rather than assumed to be a harmless side effect.
Is the 7.2 mg dose available in the UK?
The 7.2 mg dose is available in the UK, but only on a private prescription.
The MHRA approved Wegovy at doses of up to 7.2 mg once a week on 6th January 2026, for adults living with obesity who have a BMI of 30 or above.5
At first, that dose was given as three separate 2.4 mg injections each week, and the MHRA approved a single-dose 7.2 mg pen on 14th April 2026.5
NICE hasn’t recommended the 7.2 mg dose for NHS use, so it isn’t routinely available on the NHS.
The 22.9% rate of dysaesthesia applies to the highest licensed dose, which most people taking Wegovy in the UK aren’t on. At 2.4 mg, the rate in STEP UP was 6.0%.1
Wegovy is also under additional monitoring in the UK, which is what the black triangle symbol on the packaging means.2 You or your prescriber can report a side effect directly through the MHRA’s Yellow Card scheme.
Why Wegovy can cause dysaesthesia
A cause for these sensations hasn’t been established, and Wegovy’s product information doesn’t offer an explanation.2
A 2026 review of reports across the GLP-1 medication class found the same altered sensations with semaglutide, tirzepatide, and exenatide, and no settled explanation for any of them.6
Wegovy’s U.S. prescribing information states that the number of people affected rose as the dose and the amount of the drug in the blood increased, which aligns with the trial figures going from 6.0% at 2.4 mg to 22.9% at 7.2 mg.3
Among 38 people who reduced or paused their dose and then returned to 7.2 mg, 17 of them (45%) reported that dysaesthesia had returned.3
So we can be confident the medication is causing it, even if we don’t know how.
Semaglutide mimics GLP-1, a hormone we release from the gut after eating. GLP-1 reduces hunger and cravings, and slows digestion.
Neither effect explains a change in skin sensation.
GLP-1 receptors, the places on a cell where that hormone attaches, aren’t only in the gut and the brain’s appetite centres. They’re also on the sensory nerve cells that carry touch and temperature signals from the skin.
So the most common explanation is that semaglutide attaches to those receptors and changes the signals those nerves send.
The animal research doesn’t support it, though. When GLP-1 medications were injected directly into the spinal cord in rats and mice, pain sensitivity fell by 60 to 90%.7
In people living with diabetic nerve damage, these medications appear to improve nerve function rather than worsen it.
So there’s a logical connection between semaglutide interacting with our sensory nerve cells and causing these tingling sensations, but the effect people report is the opposite of what the animal research predicts. Nobody has explained that difference yet.
Rapid weight loss and low vitamin B12 are the two explanations suggested most often, and neither has been shown to explain what the trials found.
People on 7.2 mg lost more weight as well as taking more of the medication, so weight loss is a possible cause.
But weight loss differed by only around 3 percentage points between the two doses, while the rate of these sensations went from 6.0% to 22.9%.
Low B12 does cause tingling, though it’s an unlikely explanation for something reported by nearly 1 in 4 people at the higher dose.
What you can do about it
Tell your prescriber when these sensations start, even if they’re mild. They can check whether something else is causing it and adjust your dose if needed.
There’s no specific treatment for the sensations themselves, and for most people they settle without one.1
Because these sensations are linked to higher doses, the usual solution is to lower the dose you’re on.
Among people affected at 7.2 mg, 23% had their dose reduced, 8% paused treatment, and 2% stopped permanently.3
If your prescriber reduces or pauses your dose, it’s worth asking what the plan is for your treatment in the long term.
Staying at 2.4 mg is a reasonable option to discuss. In STEP UP, tripling the dose from 2.4 mg to 7.2 mg added roughly 3 percentage points of extra weight loss on average.1
Many people do well at 2.4 mg without needing to go up to the 7.2 mg dose.
While your diet is unlikely to influence these sensations, we still recommend eating a diet based primarily on whole foods to ensure you’re providing your body with all of the essential nutrients and minerals it needs to function.
When to speak to your prescriber
Most of these sensations are mild and pass on their own; we’d recommend you contact your GP or prescriber if you have:
- Numbness or tingling that spreads, becomes severe, or doesn’t go away
- Weakness in your hands or feet, or trouble with balance or fine movements like doing up buttons
- Any change to your bladder or bowel control alongside the numbness
If numbness comes on suddenly, affects one side of your body, or comes with slurred speech, facial drooping, or confusion, call 999. These can be signs of a stroke and aren’t related to Wegovy.
Some people hold back from mentioning this side effect, worried that the medication will be stopped. But in most circumstances, your prescriber will just recommend lowering your dose.
By telling your prescriber early, you give them the best opportunity for managing this while continuing your treatment as planned.
Frequently asked questions
Does Wegovy cause tingling in the hands?
It can. Tingling, pins and needles, or numbness was reported by 22.9% of people on the 7.2 mg dose in the STEP UP trial, and by 6.0% of people on the 2.4 mg dose.1
The hands, fingers, and feet are where people notice it most.
Is tingling on Wegovy a sign of nerve damage?
Peripheral neuropathy isn’t listed as a side effect of Wegovy in its UK product information, while dysaesthesia is.2
In STEP UP, these sensations were mostly mild to moderate and most recovered while people continued treatment.1
Numbness that spreads, worsens, or comes with weakness should still be checked, because it has other possible causes.
How long does the tingling last?
Most of these events resolved before the trial ended.1 Among people on 7.2 mg who developed them, 18% hadn’t recovered by the time the 72-week trial finished, so they can last months.3 Tell your prescriber if it isn’t settling.
Does the tingling go away if I stay on Wegovy?
Usually, yes. Most of these events in STEP UP recovered while people kept taking Wegovy, and only 4 people out of around 1,000 on the 7.2 mg dose stopped because of it.1
Is the tingling worse on the 7.2 mg dose?
It’s more common at 7.2 mg. These sensations were reported almost four times as often at 7.2 mg as at 2.4 mg, at 22.9% compared with 6.0%.1
If it appears after a dose increase, your prescriber may recommend maintaining at this dose until the sensations subside, before increasing the dose further.
Will the tingling come back if I go back up to 7.2 mg?
It might. Among 38 people who reduced or paused their dose and then went back up to 7.2 mg, 45% had the sensations return.3 That’s worth discussing with your prescriber before you increase the dose again.
Can Ozempic cause tingling too?
Yes. A 2026 review of side effect reports found the same altered skin sensations across the GLP-1 medications, including semaglutide, tirzepatide, and exenatide.6
Ozempic contains the same drug as Wegovy, semaglutide, though it’s licensed for type 2 diabetes and given at lower doses.
Should I stop Wegovy if I get tingling?
Not on your own. Most of these sensations are mild and settle without stopping, and only 2% of the people affected at 7.2 mg stopped permanently.3
Speak to your prescriber before changing anything, particularly if the sensation is spreading or getting worse.
Will taking vitamin B12 help?
There’s no evidence that B12 supplements treat these sensations. Low B12 is a separate cause of tingling that your prescriber may want to rule out, but the sensations in the trials tracked the dose of Wegovy and its effect on these sensations rather than B12 levels specifically.3
Why does the Wegovy leaflet say tingling is uncommon?
The ‘uncommon’ frequency on the leaflet comes from the earlier trials, which tested doses up to 2.4 mg. The product information adds a footnote saying the frequency is higher at 7.2 mg, and quotes 21.6% for that dose against 0.3% on placebo.2
Take home message
Tingling, pins and needles, or numbness, known as dysaesthesia, is a recognised side effect of Wegovy and is listed in its UK product information.2
It’s much more common at the higher 7.2 mg dose, reported by 22.9% of people in STEP UP, than at the standard 2.4 mg dose, where the figure was 6.0%.1
The 7.2 mg dose is only available privately in the UK, so most people taking Wegovy here are on a dose where this is far less common.5
For most people, these sensations are mild to moderate and settle while they carry on taking Wegovy, and 4 people out of around 1,000 on the 7.2 mg dose stopped because of it.1
It’s most likely that your prescriber would recommend lowering your dose until the sensations eased rather than stopping the medication.3
There’s no established evidence that Wegovy causes the lasting nerve damage of peripheral neuropathy, which isn’t listed as a side effect.2
Numbness that spreads, worsens, or comes with weakness should still be checked, because tingling has other causes worth ruling out.
Second Nature’s programme combines medication with personalised nutrition guidance from registered dietitians and nutritionists, built around a balanced plate of vegetables, protein, complex carbohydrates, and healthy fats, so you’re supported to eat well while you lose weight.
A peer-reviewed study published in JMIR Formative Research found that active subscribers on Second Nature’s semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss.8
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
